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1. Introduction 
Medical research based on animal model is rightly considered a “necessary evil”, being a 
“modus vivendi” in all research activities for more than 2,000 years. It is admitted that the 
major breakthroughs in medicine such as blood circulation, respiration physiology, the 
hormonal system used for research purpose different species of animals. In the last 150 
years animals used in medical experiments brought huge benefits to humanity by provid-
ing crucial responses to the most intriguing questions about prevention and treatment of 
some devastating diseases. Furthermore, diseases as cancer, AIDS, malaria, tuberculosis, 
influenza, Alzheimer’s disease and diabetes mellitus were approached by creating specific 
animal models with respect to pathogenesis, genetic insights and treatment. Despite to all 
these achievements, over the years a lot of people or organizations were and still are re-
luctant to animal research because this brings intolerable suffer and pain. All of those 
mentioned emphasized that animal models are not the only scientific methods to achieve 
important and reliable results. Consecutively, it was constantly sustained that animal 
research should be abandoned at once and further efforts should be invested in creating 
alternative methods. For preventing barbarity against animals which was rightly con-
demned in the past, new concepts were necessary to be enforced. Thus, “animal rights” 
(animals are granted to live a life free from abuse and exploitation which also includes 
prevention of use an animal for scientific research) and “animal welfare” (for the animals 
used in research this implies assessment of breeding, transport, housing, nutrition, disease 
prevention and treatment, handling and, where necessary, euthanasia) were two of the 
most invoked [1].  
Laboratory animal welfare was first defined in The Principles of Humane Experimental 
Technique written by William Russell and Rex Burch. The essence of this work refers to the 
three Rs (3Rs): 
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- refinement: decrease in the incidence of the severity of inhumane procedures applied to 
those animals used for research purpose; 
- reduction: reduction in the number of animals used to obtain information of given 
amount and precision; 
- replacement: the substitution of conscious living animals with insentient materials. 
Nevertheless, the 3Rs were the subject of dispute between animal research supporters and 
those who are against animal experimentation. Animal welfare was consistently improved 
by implementing of the 3Rs, but some important issues were created in some area of 
medical research. For instance, validation of the alternative methods which replaces the 
animals, reliable results based on statistical analysis when a smaller number of animals are 
used or refinement of the methods for induce less pain and suffering (e.g. administration of 
analgesics after surgical procedures) were the most debated in the last forty years. The 
scientific world is still preoccupied by further implementing of the 3Rs [2, 3]. In USA, 
National Institute of Health stopped financing almost all new projects which use 
chimpanzees as the closest human’s related animal model [4]. This species become 
nonessential due to alternative research tools and methods, this being one of the last benefits 
of Russell’s and Burch’s 3Rs.  
2. Experimentally induced hyperglycemia 
Hyperglycemia is one of the most important signs of diabetes mellitus, both surgical 
removal of the pancreas and administration of β-cell toxins being equally used. The first 
method has been used for the first time in a canine model designed by Oskar Minkowski 
and Josef von Mering. Partial or total surgical removal of the pancreas was followed by the 
most “popular” clinical sign of diabetes: glucosuria, body weight loss despite voracious 
appetite and intake of nourishing food, polyuria, polydipsia and ketonuria [5, 6]. This 
experiment was followed by another historical breakthrough accomplished by Frederick 
Banting and Charles Best. These two scientists performed a ligation of pancreas ducts to 
induce atrophy of exocrine acinar component and thereby to obtain a less contaminated 
extract of pancreatic islets. This extract succeeded to determine a substantial prolongation of 
life in dogs with pancreatectomy and also to save the life of a diabetic boy [7].  
It is well known that the beginnings of the research in diabetes aimed as animal model the 
dogs and the rabbits. Later, the scientists preferred to conduct experiments in smaller ani-
mals, these being easier to manipulate and involve smaller expenses. Thus, rats and mice 
were subjected for pancreatectomy. This surgical procedure is challenging because of the 
particular anatomy of the pancreas and pancreatic ducts in this species. The rat pancreas is 
spread on a large anatomic area, being divided in three parts (biliary, duodenal and gastro-
splenic portions). The duct system is quite polymorphic and represented by numerous in-
dependent pancreatic ducts which drain secretion from each corresponding part. The results 
of pancreatectomy in rat were not always followed by the rapid onset of the diabetes and do 
not reflect entirely the diabetes in humans, these being speculated by those who consider 
that larger species are more appropriate for diabetes study [8, 9]. 
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Toxins as streptozotocin [10], alloxan [11], vacor [12], dithizone [13], and 8-
hydroxyquinolone [14] were used as non surgical methods. Each toxins aim to induce 
various destruction of β-cells and produce diabetes and subsequent complications.  
Both surgical removal of the pancreas and toxin induced diabetes are valuable methods 
used for studying the consequence of hyperglycemia and the onset of diabetes complica-
tions such as diabetic microangiopathy and macroangiopathy, retinopathy, neuropathy, and 
cardiomiopathy. Cardiomiopathy, as a complication of streptozotocin induced diabetes was 
revealed by gravimetric assessments and morphometry. Diabetic rats present hypertrophy 
of left ventricle, revealed by increased values of ventricular ratio, comparing with control 
group. Same groups exhibited significant increasing of heart weight/body weight ratio and 
liver weight/body weight ratio, comparing with control group [15]. Considering that cardiac 
hypertrophy is the result of potential interstitial fibrosis, thickening of arteriolar media, 
endothelial cells and basement membrane changes, morphometry of arteriolar media of 
heart arterioles and cellular density of media were assessed. Arteriolar media/diameter of 
arteriolar lumen was significantly bigger in rats with streptozotocin induced diabetes, this 
being the result of fibrosis in arteriolar media [16].  
Islet cell transplantation and its consequence is one of the current research targets, being 
conducted on either surgical removal of the pancreas and toxin induced diabetes. Successful 
transplantation was achieved for the first time in 1966 in patients with diabetic nephropathy 
subjected for simultaneous pancreas and kidney transplantation [17]. Despite to consistent 
benefits of this therapeutic management, the lack of donors, the acquired chronic 
immunosupression, postoperative complications and graft rejection have to be considered. 
Thus, islet transplantation era began with two experiments in rodents previously rendered 
diabetic by the methods described above [17-19]. The methods of transplantation became more 
refined correlated with and requested by all the shortcomings resulted by immunosupression 
and graft rejection. Therefore, pancreatic islets graft may be transplanted as alginate or 
alginate-polylysine immunoisolated microcapsules [20-22], which are implanted in various 
anatomic sites (subcutaneously, into the splenic parenchyma, under renal capsule, into the 
peritoneum, into the portal vein for further colonization in the liver) [17-19, 23]. Unfortunately, 
the lifetime of transplanted islets is shortened by the deleterious immune reaction of the host. 
Without microcapsule protection and immunosuppressive treatment, islets transplanted into 
the liver are immediately surrounded by thrombi placed into the vessels of the surrounding 
tissue. Allogeneic islets from liver and spleen present lymphocytic infiltrations in 2 days after 
transplantation and are destroyed rapidly by the host [24]. 
Diabetic rodents are frequently used in research concerning pharmaceutical compounds 
aimed to lower the level of glycemia in diabetic persons. New formulas are previously tested 
on diabetic rodents in order to estimate efficacy, and potential toxic effect on the patients.  
3. Experimentally induced glycosuria 
Phlorizin is an organic compound, member of chalcone class, extracted for the first time 
from the bark of the apple tree. The compound was also isolated from roots bark, shoots, 
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leaves and fruits, proving that phlorizin is usually ingested by humans. It was observed that 
ingestion of more than 1g of phlorizin is followed by glycosuria. Knowing that diabetes 
mellitus expresses urinary symptoms such as glucosuria and polyuria, an important correla-
tion has been made between these symptoms and the effect of phlorizin. Chronic admin-
istration in dog was followed by glucosuria, polyuria and weight loss, creating this way an 
obvious resemblance between human spontaneous diabetes mellitus and phlorizin effect 
[25]. Diabetic rats treated with phlorizin express values of glycemia almost equal with nor-
mal parameter. This model was used to clarify the implication of hyperglycemia in the pro-
gression of islet lesions. The results proved that chronic hyperglycemia might have no effect 
of islets histopathological changes [26].  
4. Chemically induced insulin dependent diabetes mellitus – animal 
models 
Considering that insulin dependent diabetes mellitus (IDDM) features the immune-mediated 
destruction of β-cells and subsequent insulinopaenia, animal models which reproduce 
damage of pancreatic islets have been created. For this purpose, streptozotocin and alloxan 
induced diabetes mellitus were considered the handiest manners to create this condition, 
although naturally, β-cells become dysfunctional after a long period without evident clinical 
signs. Streptozotocin and alloxan are diabetogenic chemicals, both being framed in the group 
of glucose analogues. The onset of β-cells destruction is induced via different mechanisms. 
Alloxan was the first used as a toxic agent against β-cells, its ability being to generate both 
reactive oxygen species (ROS) and inhibition of glucose mediated insulin secretion through 
glucokinase blockage. During the destructive process, β-cells express reversible 
transformation of cytoplasmic organelles (cytoplasmic vacuolization, dilation of rough 
endoplasmic reticulum, reduced Golgi apparatus, scattered insulin content secretory granules 
and swollen mitochondria) finalizing with irreversible damaging of DNA (TUNEL positive 
staining of β-cells nuclei) [11]. Streptozotocin has antibiotic and chemotherapeutic properties, 
being isolated from Streptomyces achromogenes. The main action of streptozotocin is focused 
on β-cells DNA via alkylation process. Finally, DNA methylation results into the 
fragmentation and ultimately generates cell death [11, 14, 27]. Streptozotocin diabetes 
mellitus can be induced via a single large dose or multiple low doses administration. It is 
possible that the first option to induce diabetes because of direct toxic effect of streptozotocin, 
while, low doses repeatedly administrated may exert blockage of insulin secretion [14]. 
Other diabetogenic compounds were used in experimental models such as dithizone [28]. 
Administration of this chelator in rabbit has a particular effect expressed as initial hypergly-
cemia after 2 hours, followed by normoglycemia in 8 hours and finalized by permanent 
hyperglycemia due to degranulation of β-cells [29]. 
5. Spontaneous IDDM based on animal models 
The non-obese diabetic (NOD) mouse (table 1) is a spontaneous IDDM animal model. This was 
spontaneously obtained in one of two sublines derived from CTS mice (Immune Deficiency 
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of Cataract Shionogi). The diabetic line was established after six generations of breeding 
[30]. About 20% of males and 80% of females develop type 1 diabetes mellitus around 30 
weeks of age in particular environment (the incidence of diabetes is higher in colonies main-
tained in relatively germ-free conditions). The lesions of Langerhans islets are expressed as 
insulitis, the onset of insulinopaenia being recorded in 12-week-old females. Polyuria, poly-
dipsia, hyperglycemia, glucosuria and hypercholesterolemia are the main clinical signs [30, 
31]. Daily administration of insulin improves consistently the body weight and life span, 
although the mice can survive for weeks without insulin supplement. It is noteworthy that 
the low level of insulin in NOD mice is correlated with increase secretion of glucagon in 
treatead and non-treated with insulin individuals. Thus, is concluded that insulin deficiency 
and glucagon hypersecretion might have an important role in the development and clinical 
progress of diabetes in NOD mice [32]. Pinealectomy in newborn mice is followed by a more 
rapid onset of diabetes in female and supplementary melatonin administration protects the 
animals. The results are somehow intriguing, knowing that melatonin induces increase of 
insulin autoantibodies [33]. NOD mice are prone to develop autoimmune inflammations, 
especially those with anti-diabetogenic MHC haplotype and programmed death cell defi-
ciency (sialadenitis of submandibular gland, thyroiditis, gastritis, vasculitis of renal arteries, 
neuritis) [34-36]. The most important studies which have been run on NOD mice targeted 
gene implication, MHC genes class II having an important role. Also, knowing that NOD 
mouse develop cell immune mediated diabetes, many of the experiments aim to picture the 
immunological status which is responsible for the onset of diabetes [37, 38]. It is important 
to bear in mind that diabetes in NOD mice is not only the result of cell mediated immunity 
but also of humoral factors as GAD and IgM [39].  
Akita mouse (Ins2Akita) was obtained from a spontaneous point mutation in a female of 
C57BL/6 line. This mutation disrupts normal synthesis of insulin via incapacity to produce 
and secrete mature insulin. Clinical signs of diabetes are clearly expressed in male, compar-
ing with female. Heterozygous mutant mice present hyperglycemia, hypoinsulinemia, pol-
ydipsia and polyuria. The mice are lean and do not present insulitis. Pancreatic islets exhibit 
decreased density of β-cells and decreased density of secretory granules in the existing β-
cells, increase amount of endoplasmic reticulum and swollen mitochondria [40]. Progressive 
diabetic retinopathy begins around 12 weeks of age after the onset of hyperglycemia and is 
consistent with increased vascular permeability, morphological abnormalities of astrocytes 
and microglia, apoptosis and thinning of inner layer of the retina [41]. Heterozygous Ins2Akita 
are suited for allogeneic and xenogeneic islet transplantation, because it provides a biologi-
cal status free of unwanted toxic effect of streptozotocin and alloxan and without β-cell 
autoimmunity [42].  
BB (bio breeding) rat also known as BBDP (bio-breeding diabetes prone) rat is an inbred laboratory 
rodent which spontaneously develops IDDM. The animals between 2 and 4 months of age 
develop spontaneous hyperglycemia, different degrees of mononuclear infiltration of the 
pancreatic islets or total loss of β-cells, insulinopaenia and ketogenesis [43-45]. The overt 
diabetes can be reversed in 36% of diabetic rats when BB/Worchester (BB/W) are treated 
with rabbit anitiserum to rat lymphocytes. These results highlight that diabetes mellitus in 
BB rats is a cell-mediated autoimmune disease [46]. Destruction of β-cells is performed 
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Rodents 
Mouse 
Non-obese diabetic (NOD) mouse 
Akita mouse 
Rat 
BB/BBDP 
Long Evans Tokushima Lean (LETL) 
Komeda Diabetes Prone (KDP) 
Rabbit New Zealand White Rabbit 
Hamster Chinese hamster (Cricetulus griseus) 
Dog Keeshond dog 
Table 1. Animal models for insulin dependent diabetes mellitus 
by a cohort of immune cells such as T and B-lymphocytes, macrophages and natural killer cells 
[38, 47]. The BB/Worchester diabetic rats may develop lymphocytic thyroiditis in individuals 
between 8 and 10 months of age [48]. The onset of diabetes in BB rats is attributable to many 
genes, the most important being those which trigger the age of the onset of diabetes, diabetes 
susceptibility, severity of islet infiltration with inflammatory cells and islet atrophy [49].  
As an overview of either differences or resemblances between NOD mouse, BB rats and 
human IDDM data are presented in table 2 [50]. 
 
Characteristics Human NOD mice BB rats 
Genetic predisposition (MHC class II) yes yes yes 
Genetic control polygenic polygenic polygenic 
Haemopoietic stem cell transfer yes yes [50] yes [50] 
Lymphocytic insulitis (with T-lymphocytes) yes yes yes 
Lymphocytic infiltrates in other organs sometimes yes yes 
Humoral reactivity to β-cells yes yes [39] no 
Diabetic ketoacidosis (without treatment) yes mild yes 
Detection of retroviral antigens expressed in beta cells no yes [51] no 
Sex predisposition no yes no 
Table 2. Comparative overview in human, NOD mouse and BB IDDM 
Long Evans Tokushima Lean (LETL). An outbred colony of Long-Evans rats developed 
spontaneously remarkable signs attributable to diabetes (polyuria, polyphagia, and 
polydipsia). This line has been maintained since 1983 in Tokushima Research Institute 
(Otsuka Pharmaceutical, Yokushima, Japan) and generated another line (Long Evans 
Tokushima Lean - LETL). LETL rats present no sex predilection concerning the onset of the 
disease or severity, sudden onset of the diabetes expressed as hyperglycemia, polyuria, 
polydipsia and weight loss, lymphocytic insulitis at 120-220 days of age followed by the 
destruction of β-cells, normal levels of T-lymphocytes, lymphocytic infiltration of salivary 
and lacrimal glands [52, 53].  
Komeda Diabetes Prone (KDP) rat is a substrain of LETL, all the individuals presenting mod-
erate to mild insulitis around 220 days of age. The onset of diabetes is 70% at 120 days and 
82% within 220 days. This strain present a major IDDM susceptibility gene named 
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Iddm/kdp1 placed on chromosome 11. Homozigous alleles at this locus are strongly linked 
with the capacity to develop moderate or severe insulitis [54-56] 
New Zealand White Rabbit developed spontaneous diabetes mellitus for the first time in a 
female in 1969. By inbreeding this female and her offspring, a diabetic line was obtained. 
The overt diabetes was diagnosed in 19% of animals aged between 1 and 3 years. The 
diabetic animals present fasting hyperglycemia, hypoinsulinemia and absent ketoacidosis 
[57]. The lesions of β-cells are expressed as cytoplasmic hypergranulation, this being 
different comparing with previous animal models featured by insulitis, islet atrophy, 
degranulation of β-cells. It was postulated that the lesion is the consequence of a secretion 
defect. In addition, diabetic rabbits present mineral deposits in kidney, particularly in 
basement membrane of the tubules and Bowman capsules and into the lining cells of 
proximal convoluted tubules [58, 59].  
Certain lines of Keeshond dog may develop inherited IDDM expressed as overt diabetes 
around 2-6 months of age. The dogs have low level of insulin as a consequence of β-cells 
aplasia. In addition, glucagon secretion is also depressed. The dogs can survive 2-4 months 
without insulin supplement. Concurrent lesions such as cataracts, skin infections and poor 
bodily growth are observed. The incidence of diabetes is higher in females. The fertility in 
diabetic individuals is very low, non-diabetic dogs being used to obtain diabetic offspring. 
An autosomal recessive disorder is consistent with the onset of diabetes. Keeshond dogs are 
suitable for studying long term complications of diabetes [60, 61]. 
Chinese hamster (Cricetulus griseus) has become the subject of research in diabetes mellitus as an 
animal model since 1959 [62]. The incidence of diabetes in Chinese hamster sublines is more 
than 85%. At the time of birth, the pups are prediabetic. The overt diabetes range from mild to 
severe and it is characterized by polyphagia, hyperglycemia, severe polyuria, glucosuria and 
elevated gluconeogenesis. β-cells present degranulation and hydropic degeneration [63-65]. 
Other morphologic changes occur in kidneys (glomerulosclerosis), brain (vascular lesions 
expressed as duplication and thickening of the basement membrane, degeneration in either 
dendrites or axons, focal demyelination and synaptic degeneration) [66], exocrine pancreas 
(pancreatic adenoma and adenocarcinoma) [67], teeth (periodontal disease) [68], and 
macroangiopathy of the thoracic aorta [69]. Genetic defects are responsible for the onset of 
diabetes, four autosomal recessive genes being involved [70]. Chinese hamster with IDDM 
have an impaired humoral antibody response similar to that developed in human diabetes, 
which makes it suitable for research concerning the consequence of diabetes mellitus induced 
by impaired immune response [71], as well as for diabetic nephropathy [72]. 
6. Animal models of non-insulin dependent diabetes mellitus (NIDDM) 
NIDDM is generated by the failure of β-cells to adapt to a more challenging conditions 
created by insulin resistance, this being induced by over-nutrition and lack of physical 
exercises. Mechanisms as oxidative stress, islet amyloidosis, glucotoxicity and lipotoxicity 
were associated with inappropriate secretory behavior of β-cells. Autoimmune attack and 
islet inflammation considered previously as a hallmark for IDDM, is now associated with 
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NIDDM. This concept is sustained by the fact that all mentioned mechanisms may initiate 
inflammation or are initiated by the inflammation. One of the reasons is that human 
pancreatic islets release IL-1β as response to glucotoxicity. The inflamation is somehow 
blocked in the initial stages for allowing β-cell regeneration. The more necrosis and 
apoptosis become obvious, the more infiltration with inflammatory cells (e.g. macrophages) 
are seen in pancreatic islets [73, 74].  
Creation of animal models of NIDDM needs to meet the heterogeneous background which 
features human condition. Roughly, the animals have to express insulin resistance, impaired 
insulin secretion in the condition of fasting or post-challenge hyperglycemia. On the other 
hand the existent animal models present as dominant at least one characteristic: some 
animals are insulin resistant, other express mainly glucose intolerance as a part of obesity, 
others express NIDDM because of a particular sensitivity to dietary components. The animal 
models used for research in NIDDM present an important diversity, although mice and rats 
are constantly preferred (table 2).  
 
Rodents 
Mouse 
Obese 
ob/ob mouse
db/db mouse 
KK mouse 
NZO mouse 
NONcNZO10 mouse 
NSY mouse 
TH mouse 
TSOD mouse 
M16 mouse 
CBA/ca mouse
Gene mutation 
Diet induced C57/BL 6J mouse Diet-gene interaction 
Rat 
Obese 
ZDF rat
Wistar fatty rat 
OLETF rat 
SHR/NIH-cp
Gene mutation
Non-obese 
GK rat
Torii rat
Gene mutation
Diet induced
Cohen diabetic rat
Israeli sand rat 
Nile rat
Diet-gene interaction 
Pig [75] - 
Yucatan minipig
Göttingen minipigs 
Sinclair minipigs 
Yorkshire and Yorkshire crossed strains
Chinese Guizhou minipig 
Ossabaw minipigs 
Familial hypercholesterolemic pigs 
Low-birth-weight pigs
Cardiovascular complications 
Cat [76] - Shorthaired males Islet amyloidosis 
Monkey [77] - Non human primates Islet amyloidosis 
Table 3. Animal models for NIDDM 
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Ob/Ob mouse was created in Jackson Laboratories in 1949 and resulted from mutation on 
both obese (ob) genes [78]. The main characteristic of this mutant is the uncontrolled 
appetite which results rapidly in the onset of obesity and NIDDM around 11 weeks of age. 
Polyphagia in ob/ob mouse is generated by ob genes mutations which also encode leptine. 
This hormone is synthesized by adipose tissue and has an important role in appetite 
downregulation and regulation of body weight. Leptin is absent in obese mice, the 
treatment with this monomer lowers consistently the food intake and body weight and also 
improve up to normal the plasma levels of glucose and insulin [79]. Persistent mild 
hyperglycemia is linked with 60% enlargement of pancreatic islets and subsequent 
hyperinsulinemia comparing with lean mice. Interestingly, β-cell from obese mice secretes 
insulin at a lower threshold of glucose that lean mice [80]. High level of plasma insulin may 
result from metabolic alteration of β-cells that leads to insulin overproduction or is the 
consequence of the heterogeneity in glucose sensitivity of these cells. Increased 
concentration of glucose is followed by recruitment of new β-cells with increased glucose 
sensitivity [81]. Infertility is a current feature in obese mouse, this being supported by fatty 
degeneration of the ovaries, follicular atresia, damaged mitochondria and apoptosis of the 
ovocytes [82]. Many studies have been run in ob/ob mice such as amelioration of insulin 
resistance [83], hypoglycemic effects of some polysaccharids [84, 85] and complication of 
NIDDM as diabetic cardiomiopathy [86] and peripheral neuropathy [87]. 
Db/db mouse is a diabetic mutant mouse created in Dunn Nutritional Laboratory, Cambridge, 
United Kingdom in 1966. Particularly, this mutant expresses a mutation on db gene which 
encodes the leptin receptor [88]. Thus, leptin signaling in the hypothalamus is absent leading 
to persistent high levels of both insulin and leptin. The mouse becomes obese around 4-6 
weeks of age and develops progressively high levels of plasma insulin and glucose. All 
characteristic clinical signs are recorded: polyuria, polydipsia, polyphagia, proteinuria, and 
glucosuria. One of the most intriguing aspects is that the mice of some strains maintain 
hyperinsulinemia despite severe depletion of β-cells. This can be attributed to stem cells 
differentiation from pancreatic ducts. Body weight and insulin levels begin to decrease in 
association with β-cell degeneration when the mouse reaches 5-6 months of age. The cause of 
death remains unclear, although the mice present ketonuria, hematuria and gastrointestinal 
hemorrhages in terminal stage [89]. Db/db mouse has a long history in comparative research to 
human diabetes. Thus, human dietary habits were reproduced in db/db mouse. High lipid and 
cholesterol reach diet induce dyslipidemia and create similarities with the patients with type 2 
diabetes mellitus [90]. Furthermore, diabetic nephropathy in db/db mice is consistent with 
some features encountered in human diabetic nephropathy such as renal hypertrophy, 
glomeruli enlargement, albuminuria, and mesangial matrix expansion [91].  
KK mouse history began in 1957, this line being derived from numerous strains of Japanese 
native mice. Later, after many inbreeding procedures, Nakamura obtained KK mouse strain, 
which was a polygenic model, spontaneously diabetic and named after the region where the 
strain was founded (Kasukabe in Saitama prefecture) [92]. The KK mice become obese once 
with the onset of adulthood and develop insulin resistance, subsequent hyperinsulinemia 
and β-cell hyperplasia. Particularly, KK mice present a chemical diabetic stage preceded by 
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prediabetes stage accompanied by renal, neurological and retinal complications [93]. The 
severity of diabetes is strongly correlated with environmental factors such as diet, food 
intake and social isolation of the animals, the chemical diabetic state being replaced with 
overt diabetes [94, 95]. Diabetes and obesity in KK mouse has a moderate expression. 
Introduction of Ay allele creates a new line (KK- Ay) which present enhanced 
pathophysiological characteristics especially for glucose intolerance [96].  
New Zealand obese (NZO) mouse is a polygenic animal model which is prone to express 
obesity, insulin resistance, glucose intolerance and also autoimmunity featured by 
perturbation of splenic lymphocyte function and IgM antibodies to insulin receptor. These 
characteristics are concomitant with poor breeding performance due to ovarian 
degeneration [97] and diabetic nephropathy expressed as glomerular proliferation, 
mesangial deposits, mild thickening of basement membrane, glomerular eosinophilic 
nodules and glomerulosclerosis [98-100]. There are research which concluded that the 
obesity develops independently to dietary content, the onset of diabetes being recorded 
earlier in mice fed with carbohydrates and fat reach diet [101]. Other studies emphasized 
that obesity in NZO individuals is the results of hyperphagia and low energy expenditure 
due to insufficient physical activity [102].  
NONcNZO10 mouse is a recombinant congenic new strain of NIDDM developed by 
introgressing 5 genomic intervals containg NZO/H1Lt (NZO) diabetogenic quantitative trait 
loci onto non-obese non-diabetic (NON/Lt or NON) genetic background [103]. Particularly, 
these mice do not express polyphagia, morbid obesity, poor fertility and variable frequency 
of hyperglycemia as their parental NZO males do. NONcNZO10 males are normophagic, 
moderately obese and exhibit normal fertility. NONcNZO10 males become hyperglycemic 
in 12-20 weeks of age and present atrophy of pancreatic islets and hepatic lipidosis. The 
resemblance between NONcNZO10 mice and human obesity/diabetes syndrome in higher 
than ob/ob and db/db mice because of lack of hyperphagia, normal levels of leptin and 
leptin signaling, normal thermoregulation and lack of hypercorticism [104].  
Nagoya-Shibata-Yasuda (NSY) mouse is a spontaneous model of NIDDM, having the same 
ancestor with NOD mouse (Jcl ICR line). Surprisingly, three major loci contributing to 
susceptibility to NIDDM in the NSY mouse presented overlapping with the region where 
susceptibility genes for IDDM have been mapped in NOD mouse. It was postulated that some 
responsible genes for the onset of diabetes come from the same ancestor genes which express 
IDDM phenotype in NOD mice and NIDDM in NSY mice [105]. Age and sex related onset of 
diabetes is the most prominent characteristic for NSY mice. Males develop diabetes at 48 
weeks of age as mild obesity and mild hyperinsulinemia. The impaired insulin secretion via 
glucose challenge is observed after 24 weeks of age. There were no morphological changes in 
pancreatic islets in NSY mice at any age, these findings suggesting that defective secretion of 
β-cells may be one of the causes in NIDDM in the NSY mouse. Fasting hyperinsulinemia may 
contribute to the pathogenesis of diabetes in NSY mouse, insulin sensitivity being under 
genetic control of Nidd2nsy and Nidd3nsy genes. Genetic analysis of NSY identified a specific 
gene mutation of Tcf2 responsible for encoding hepatocyte nuclear factor 1β (HNF-1β) and 
implicated in MODY pathogenesis [106, 107]. Spontaneous amyloidosis was reported in old 
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individuals, deposits being remarked mainly in kidneys, but also in the different segments of 
digestive system, lung, heart and adrenal glands [108]. NSY mice as well as ob/ob mice prove 
recently to be the source of creating of new animal models for simultaneous development and 
research of Allzheimer’s disease and NIDDM [109]. 
TallyHo (TH) mouse is a relatively new NIDDM animal model, reported for the first time in 
2001. The mice present obesity, hyperinsulinemia, hyperlipidemia and male-limited 
hyperglycemia, insulin resistance and glucose intolerance. It has been postulated that female 
diabetes resistance is the consequence of estrogens which enhance hepatic insulin sensitivity 
[110]. The genome wide scan proves polygenic involvement and also additional gene-gene 
interactions to express hyperglycemic phenotype [111]. Comparing with ob/ob and db/db 
mice, which present severe obesity attributable to leptin synthesis and leptin receptor 
deficiencies respectively, TH has normal levels of this hormone and also intact leptin signaling. 
Carbohydrates and fat reach diet enhance the levels of leptin and also the other specific 
features of NIDDM [112]. The treatment with leptin results in decreased glucose-stimulated 
insulin secretion, which demonstrate that letin plays an important role in initiation of glucose 
intolerance in TH mice [113]. Both males and females develop early moderate hyperplasia and 
hypertrophy of pancreatic islets, but only the males continue these lesions with β-cell 
degranulation, discrete vacuolization, different degrees of islet atrophy and fibrosis [114]. 
Vascular dysfunction occurs in TH mice, expressed mainly in aorta, carotid arteries and 
cerebral arterioles as a consequence of PGH2/TxA2 receptor activation and cytochrome p450 
products and oxidative stress and elevated activity of Rho kinase, respectively [115, 116]. 
Tsumura Suzuki obese diabetic (TSOD) mouse resulted from inbreeding procedure of ddY 
strain. The diabetic line includes only moderate obese males with polyphagia, polydipsia, 
glucosuria, hyperglycemia, hyperinsulinemia, and hyperlipidemia. Pancreatic islets exhibit 
hypertrophy and hyperplasia, without any signs of insulitis or islet fibrosis [117]. Diabetic 
nephropathy is consistent with thickened basement membrane of the glomeruli and 
increased mesangial area. Peripheral neuropathy involves both sensitive and motor nerves 
and expresses high resemblance with human counterpart. The most prominent lesions of the 
nerve are decreased density of nervous fibers due to endoneurial fibrosis, degeneration of 
myelin sheath, intralamellar edema and remyelination, total destruction of lamellar 
structure associated with macrophage invasion around and into the myelin sheath [118]. 
Insulin resistance in TSOD mouse is probably induced, at least partially, by a decreased 
GLUT 4 translocation by insulin in skeletal muscles and adipose tissue [119].  
M16 mouse is a new obese animal model created in Institute of Cancer Research, London, 
UK. Both male and female express early onset of a moderate obesity due to hyperphagia and 
have high levels of insulin, leptin and cholesterol. The diabetic phenotype of M16 permits 
research of obesity/diabetes syndrome with early onset as it recorded in human population 
as a current tendency [120]. 
CBA/Ca mouse diabetes is recorded only in 10-20% of males. The incidence can be enhanced 
by inbreeding. Hyperphagia, obesity, hyperglycemia, glucose intolerance, hyperinsulinemia, 
hypertriglyceridemia occur around 12-16 week of age. Pancreatic islets are hypertrophied, 
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with increased insulin content that persist up to 48 weeks of age. The islet degeneration as a 
prove of β-cell exhaustion does not appear in this mouse [121, 122].  
Zucker diabetic fatty rats (ZDF rats) resulted from inbred as well as outbred lines of rats, which 
maintain hyperglycemia and glucose intolerance featuring NIDDM. The scientist Lois M. 
Zucker and Theodore F. Zucher created in 1961 a line of rats which express a gene responsible 
for the onset of obesity (fatty gene/fa). Usually these rats are not hyperglycemic and present 
leptine-receptor deficiency, although both male and female express some parameters 
attributable to insulin resistance. The original colony began spontaneously to present 
hyperglycemia and glucose intolerance in some bucks and does. These individuals were the 
founders of the Zucker diabetic fatty rats. ZDF rats develop hyperglycemia with concomitant 
β-cell death. Compensatory proliferation is maintained as long as plasma glucose levels 
remain moderate [123-125]. Subsequent exhaustion of β-cells is followed by an increased rate 
of apoptosis [126]. Lipotoxicity is also considered as a potential cause of β-cell population 
reduction. Thus, elevated lipogenesis prior to, or in association with hyperglycemia results in 
excessive accumulation of fatty acid into the β-cell cytoplasm [127]. ZDF rats are frequently 
used in comparative studies with non-diabetic fatty rats and lean ZDF.  
Besides the ZDF rats, other strains have been created, all receiving fa-gene from Zucker rats. 
Wistar fatty rats (fa/fa) resulted from mating of Zucker with Wistar-Kyoto individuals. The 
rats from this line are obese, and present hyperlypidemia, hyperinsulinemia and insulin 
resistance. Wistar fatty rats are prone to develop hypertrophy of pancreatic islets and 
degranulation of β-cells. The symptoms of diabetes have been observed only in males [125].  
Otsuka Long-Evans Tokushima fatty (OLETF) rat resulted from an outbred colony of Long-
Evans rats which spontaneously develop polyuria, polydipsia and mild obesity. The onset of 
hyperglycemia occurs in male and relatively late comparing with other lines (after 18 weeks 
of age). Particularly, OLETF rats present a specific diabetogenic gene associated with X-
chromosome Implication of testosterone is considered to have an important influence in the 
onset of diabetes in male. This feature is sustained also by the administration of estrogen in 
castrated males which suppress or delay diabetes. The lesions of pancreatic islets begin with 
discrete lymphocytic infiltration, followed by the second stage expressed as islet hyperplasia 
with or without fibrosis in or around the islets and final stage represented by islet atrophy 
[128, 129]. OLETF are prone to develop diabetic nephropathy, some features of this compli-
cation comparable with human diabetes being recorded (diffuse glomerulosclerosis, thick-
ening of basement membrane, PAS-positive deposits in the mesangium or capillaries). 
Mesangial lesions might express some nodular aspect similar but not identical with specific 
Kiemmelstiel-Wilson lesions [130]. 
Spontaneously Hypertensive rat/National Institute of Health-cp (SHR/NIH-cp) was created in 
Bethesda Maryland USA and associates obesity, NIDDM and hypertension. This rat 
presents a homozygous genotype for corpulent gene (cp/cp). The males are early 
hyperphagic and become obese and express hyperglycemia, impaired glucose tolerance, 
hyperinsulinemia, insulin resistance, high plasma levels of cholesterol and triglycerides, 
hyperleptinemia and mild essential hypertension [131]. 
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JCR/LA-cp rat (James C. Russel/LA-cp rat) was reported in 1984 as a homozygous genotype for 
cp gene which develops hyperphagia, obesity, insulin resistance, hyperinsulinemia, glucose 
intolerance, hyperlipidemia and leptin receptor deficiency. Obese males also manifest 
cardiovascular lesions such as atherosclerosis and myocardial lesions. Hyperinsulinemia is 
caused by β-cell hyperplasia followed by islet hypertrophy and fibrosis [132]. Pharmacological 
researches use this animal model to determine the effectiveness of anti-obesity compounds 
and also to evaluate long-term benefit to prevent atherosclerosis [133-135] 
Goto Kikazaki rat (GK) is one of the polygenic non-obese models of NIDDM which exhibit 
high resemblances with human condition, especially on hormonal, metabolic and vascular 
disorders. The line was founded in Japan (Tohoku University in 1975) based on selective 
repeated inbreeding of non-diabetic Wistar-Kyoto rats with minor glucose intolerance. 
Diabetes became overt and stable after 30 generations. Despite minor differences between 
subcolonies of GK, common characteristics were noticed such as decreased β-cell mass, 
moderate and stable hyperglycemia in adults, hepatic and peripheric insulin resistance and 
polyuria. Defective function and morphology of pancreatic islets was recorded since 
embryonic and fetal period featured by reduction of β-cell mass and insulin levels [136-138]. 
The complications of diabetes in GK rats refer to nephropathy (significant enhancement of 
kidney weight, glomerular volume, basement membrane thickness, mesangial fraction and 
total mesangial volume) [139], peripheral neuropathy [140, 141], diabetic osteopathy 
(trabecular osteopaenia) [142] and diabetic retinopathy (reduction of retinal blood flow, 
pericytes ghosts, acellular capillaries, increased production of vascular endothelial growth 
factor) [143, 144]. 
Spontaneously Diabetic Torii (SDT) rat has been developed from Sprague-Dawley rats in 
1997 in Research Laboratories of Torii Pharmaceutical, Ohnodai, Chiba, Japan. This rat is 
particularly characterized by non-obese, sex related onset of NIDDM with insulin hypose-
cretion and severe diabetic retinopathy. The males develop glucosuria around 20 weeks of 
age. All males are diabetic by 40 weeks, while only 33% of female rats present diabetes 
even by 65 weeks of age. Glucose intolerance is noticed in 16-week-old individuals and 
continues with the onset of hyperglycemia, hypoinsulinemia, long-term survival without 
insulin treatment and hypertriglyceridemia. Fibrosis of pancreatic islets and ocular lesions 
such as hypermature cataract, hemorrhages in anterior chamber, tractional retinal detach-
ment and subsequent retinal fibrovascular proliferation are the most important histopatho-
logical findings in SDT rats [145, 146]. The attempt to clarify the genetic basis of diabetes in 
SDT rats succeeded to identify seven quantitative trait loci which affect the levels of plasma 
glucose and one for body weight. One of them (Dmsdt1) have particular involvement in 
islet inflammation and fibrosis. It was suspected that this gene might also have implication 
in retinal lesions [147]. 
Cohen diabetic rat (CD) is a particular experimental model for study in NIDDM, which make it 
distinctive comparing with the other models presented. Diet-induced diabetes correlated with 
a genetic sensitivity is truly considered the most prominent feature of this rat, although it is 
still unclear which of the dietary components are responsible for the onset of the diabetes. It 
was observed that CD rats become overtly diabetic when their diet has a high-sucrose low 
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copper content. In addition with diet profile, a sex predilection can be observed: male record a 
lower growth rate and more severe glucose intolerance than female. CD rats fed with 
diabetogenic diet do not express obesity or hyperlipidemia [148]. Other studies concluded that 
high-casein low copper diet is responsible for the onset of the diabetes. This result is based on 
genetic analysis, a gene (Ica1) being associated with diabetes and bovine casein. Routine 
histopathological investigation reveals intact pancreas islets and replacement of exocrine acini 
with adipose tissue. Degeneration of exocrine pancreas remains intact when diabetogenic diet 
is replaced with a regular one [149]. CD rats develop early hyperinsulinemia and insulin 
resistance, followed by the exhaustion of β-cells and hypoinsulinemia. The most common 
complications are diabetic retinopathy and nephropathy [150, 151]. 
The Israeli sand rat (Psammomys obesus) is a terrestrial mammal, being mostly found in the 
desert area of North Africa and Middle East. The sand rat is another experimental model for 
diet induced NIDDM. The high resemblance with human condition derives from 
distribution of adipose tissue into the subcutaneous and visceral compartments. This animal 
readily becomes obese when the diet from the natural habitat is replaced with usual 
laboratory rat chow. It was suspected but not proved yet that some components from the 
natural diet might have hypoglycemic effect. Thus, the juice from Atriplex halimus (saltbush 
which has low energy, high water and electrolyte content and represents the basis of the 
food intake), as well as water extract and dialysate induce a significant decrease of glucose 
in diabetic sand rat [152]. The development of obesity is accompanied by hyperglycemia, 
hyperinsulinemia, decreased insulin sensitivity in adipose tissue and liver, and glucosuria, 
[153, 154]. Comparing with normoglycemic individuals, pancreatic β-cell volume begin to 
decrease in the obese and diabetic sand rats, as well as GLUT 2 glucose transporter on the 
cellular membrane and glucokinase in the cytoplasm of β-cells [155, 156]. Progressive loss of 
β-cells due to cell death is accompanied by hypoinsulinemia and persistent hyperglycemia, 
generating an irreversible diabetic state in sand rat. Proinflammatory cytokines such as IL-
1β are not involved in producing deleterious effect on β-cells [157]. However, initiation of 
inflammation in sand rat NIDDM seems to be induced by other pathogenic pathways. For 
instance, a gene named Tanis (the Hebrew word for fasting) and expressed as hepatic 
receptor for serum amyloid A (SAA) is regulated by glucose and become dysfunctional 
when diabetes occur. Knowing that SAA and other acute-phase protein received special 
attention because their implication in cardiovascular disease, Tanis gene may provide 
answers for questions about the link between diabetes, inflammation and cardiovascular 
disease [158].  
Nile rat (Arvicanthis niloticus) is a recently reported diet-induced model which expresses the 
features of both Metabolic Syndrome and NIDDM. Nile rats fed with current lab diet 
present characteristic signs as excessive abdominal adipose tissue, hyperglycemia, 
hyperinsulinemia, impaired peripheral insulin sensitivity, dyslipidemia (high level of 
cholesterol and triglycerides), microalbuminuria, and hypertension. Sex predilection was 
observed in males, which present segregation in two groups: early-onset diabetes and late-
onset diabetes. Dietary modulation (high-fat diet) induce the early onset, as well as more 
accumulation of body fat [159].  
 
Development of Improved Animal Models for the Study of Diabetes 
 
327 
7. Transgenic and knockout models used for research in diabetes 
mellitus 
The specific techniques of molecular biology had a valuable contribution for the study of 
diabetes mellitus. As it was mentioned before, diabetes mellitus involves a considerable 
heterogeneity given by the multifactorial genetic and environmental conditions. Thus, 
interpretation of the results in a particular experiment is challenged by this complicated 
background. For this particular reason, the scientists have felt the need to create transgenic 
animal model which provide good conditions for studying the effect or implication of a 
specific gene and corresponding product according to physiological and environmental 
conditions. The most important outcomes of the transgenic animals are knowledge about 
gene regulation and development, pathogenesis of diabetes and new approaches in the 
therapy of this disease. 
Transgenic animals, particularly mice, result from two basic techniques of genetic 
engineering. The first aims to transfer a gene (a new genetic material presented as a foreign 
DNA construct containing a regulatory region and a coding region for a protein), into the 
pronucleus of a fertilized ovocyte. After the gene inoculation, the modified ovocytes are 
transferred in the uterus of a foster mother for further development. After the birth, the 
pups are genetically scanned to verify whether the new genetic material was incorporated 
into the host genome. The animals which manifest the transgene are bred and the pups are 
also analyzed for the same DNA construct. Positive offspring of the second generation are 
further bred to establish a transgenic line for studying a particular transgenic phenotype. 
This revolutionary technique has both advantages and disadvantages. The major advantage 
is that the method enables to obtain transgenic animals with minimal cost and in a short 
time. The disadvantages are generated by the hazardous integration of the DNA construct in 
the genome of the host. The locus of integration, as well as the number of copies is 
unpredictable. Transgene phenotype expression is limited to use for studying a specific 
protein or RNA. Therefore, this protein will be overexpressed in the transgenic animal. If the 
target of experimentation is to reduce the expression of a protein, a RNA antisense 
transgene is used. It is noteworthy that this technique is also disadvantageous because of 
unpredictable complications and misinterpretation of the results [160].  
The second method used for obtaining genetically engineered mice is focused on deleting a 
specific endogenous gene or gene fragment (knockout) and replacing with an exogenous 
DNA which present homologous sequences with the endogenous DNA fragment 
(homologous recombination). The engineered DNA fragment (a vector which is designed to 
produce a disruption in the target gene) is inoculated in an embryonic stem cell culture. The 
positive targeted cells are inoculated in a mouse embryo, which will be finally transferred 
into the uterus of a foster mother. If the experiment is successful, this embryonic stem cells 
will participate to generate germ cells and finally organs, all having the new recombinant 
gene [161].  
Double transgenic mice can be obtained by maiting. Thus, the offspring of transgenic mice 
expressing the hemagglutinin of influenza virus under the insulin promoter and transgenic 
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mice expressing T-lymphocytes with receptor for immunodominant epitope of the same virus 
present typical features for IDDM. The mice are hyperglycemic, hypoinsulinemic, present 
lymphocytic insulitis, glucosuria and poor bodily growth, features which are consistent with 
IDDM. The mortality is up to 90% at 3 months of age [162]. This line (TCR-HA Ins-HA) has 
consistent improvement glucose levels when treated with potato buds lectin [163, 164]. 
8. Conclusions 
The experimentation in diabetes mellitus has known a long history, as well as a continuous 
and diverse development. Banting and Best as discoverers of insulin and Minkowski as the 
scientist who create the first experimental model of diabetes mellitus are truly recognized as 
the pioneers of the research in this area. Although the diversity of animal models created in the 
last fifty years is somehow overwhelming, their classification and usefulness follows the 
pathogenesis, corresponding lesions and subsequent complications recorded in human 
diabetes mellitus. The scientific literature describes many animal models of IDDM, NIDDM 
and secondary diabetes, although mice and rats are constantly used regardless the purpose of 
the research. It is easily noticed that the most famous research centers and laboratories 
developed their own experimental models and also provided genetic material for the creation 
of other colonies. Considering that hyperglycemia and glucosuria are two of the most 
important clinical signs of diabetes, some basic substances which induce these signs are 
described. Thus, Streptozotocin, Alloxan, Vacor, 8-hydroxyquinolone, Dithizone are usually 
used in experimentation which reproduce hyperglycemia, while phlorizin is recognized as a 
vegetal component which is responsible for glucosuria. The animal models of spontaneous 
diabetes mellitus are consistently represented by rodents, although other species as dog, cat, 
pig and primates are recommended. The research in NIDDM is sustained by experimental 
models divided in three major categories: obese, non-obese and diet-induced models. 
Molecular biology techniques have an important contribution in creation of transgenic animals 
for research the depth of the pathogenesis of diabetes mellitus. 
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